anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides compounds and salts of Formula I and Formula II which possessantimicrobial activity. The invention also provides novel synthetic intermediatesuseful in making compounds of Formula I and Formula II. The variables n, m, p, RA,RB, A1, R2, R3, R5, R6,R7, A8 and R9 are defined herein. Certain compoundsof Formula I and Formula II disclosed herein are potent and /or selective inhibitorsof bacterial replication. The invention also provides antimicrobial compositions,including pharmaceutical compositions, containing one or more compounds ofFormula I or Formula II and one or more carriers, excipients, or diluents. Suchcompositions may contain a compound of Formula I or Formula II as the only activeagent or may contain a combination of a compound of Formula I or Formula II and oneor more other active agents. The invention also provides methods for treatingmicrobial infections in eukaryotes.
The participants will undergo baseline assessments, including rating scales and urine opioid metabolite tests. The participants will receive one of two treatments: High-frequency (10Hz, 3000 pulses per session) dTMS using a double cone coil targeting the left dorsolateral prefrontal cortex or sham stimulation. Each treatment will be preceded by a short-guided imagery (2-3 min) design to activate the relevant brain circuitry (provocation of symptoms may increase the response rate to deep TMS as was evident in the treatment of PTSD, cigarette smoking, and OCD). dTMS sessions will be conducted 10 times per week for 2 weeks, for 20 sessions. 8 weeks of patient follow-up, including clinical visits at weeks 0, 2, and 8. During this phase, subjective and objective measures of opioid use (self-report and analysis of urine samples for opioid metabolite) will be collected. Following the completion of the main part by the individual, an "open-label" treatment using the same parameters of the experiment will be offered (regardless of the treatment group).
After IRB approval, all patients meeting inclusion criteria and requiring fasciotomy of the arms, legs, or pelvis will be consented for participation in the research study. Patients will either have their fasciotomy wounds closed through application of the Dermaclose device, as per the manufacturer's instructions, or through application of vessel loops with staples in a "shoestring technique" as described in the literature (1). Choice of wound closure technique will be at surgeon discretion. All patients will undergo application of a vacuum-assisted wound closure device (Wound VAC, Active Healing Solutions Inc, San Antonio, TX), which is standard of care for temporary coverage of open wounds (2, 3). Patients will be returned to the operating room every 2-3 days until wound closure or skin grafting has been accomplished. If skin closure is not accomplished in the operating room, but occurs prior to return trip to the operating room, then definitive suture closure of the wound will be performed under local anaesthetic, followed by removal of the Dermaclose device or of the vessel loop with staple shoestring. Decisions regarding wound closure or skin grafting in the operating room will be left to the judgment of the attending surgeon.
The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic or toxic peripheral nerve lesion or pain including, for example, neuropathic pain, inflammatory and nociceptive pain by administering to a mammal in need thereof a compound that reduces the expression or activity of BH4. According to this invention, this reduction may be achieved by reducing the enzyme activity of any of the BH4 synthetic enzymes, such as GTP cyclohydrolase (GTPCH), sepiapterin reductase (SPR), or dihydropteridine reductase (DHPR); by antagonizing the cofactor function of BH4 on BH4-dependent enzymes; or by blocking BH4 binding to membrane bound receptors. The compounds of the invention may be administered alone or in combination with a second therapeutic agent. The invention also provides methods for diagnosing pain or a peripheral nerve lesion in a mammal by measuring the levels of BH4 or its metabolites in biological sample.  Alternatively, pain or a peripheral nerve lesion may be diagnosed by measuring the levels or activity of any one of the BH4 synthetic enzymes in tissue samples of a mammal. Also disclosed are screening methods that make use of BH4 or BH4 synthetic enzymes, BH4-dependent enzymes, and BH4-binding receptors for the identification of novel therapeutics for the treatment, prevention, or reduction of pain.
While performing oxygen-related tumour treatments such as chemotherapy and photodynamic therapy, real-time monitoring hypoxia of tumour is of great value and significance. Here, we design a theranostic combination for light-activated ratiometric hypoxia imaging, hypoxia modulating and prodrug activation. This combination consisted of an oxygen-sensitive near-infrared-emitting ratiometric phosphorescence probe and a hypoxia-activated prodrug-loaded covalent organic framework. In this combination, the probe plays two roles, including quantitative monitoring of oxygen concentration by ratiometric imaging and consuming the oxygen of tumour under light excitation by photodynamic therapy. Meanwhile, the enhanced hypoxia microenvironment of tumour can raise the cytotoxicity of prodrug loaded in covalent organic framework, resulting in boosting antitumour therapeutic effects in vivo. This theranostic combination can precisely provide therapeutic regime and screen hypoxia-activated prodrugs based on real-time tumour hypoxia level, offering a strategy to develop hypoxia mediated tumour theranostics with hypoxia targeted prodrugs.
Compositions, methods, and utilities related to stabilized collagen microbubbles. Collagen microbubbles may be produced and provided in a composition comprising a stabilizer to promote longevity of the collagen microbubbles in the composition. The stabilizer may comprise a fatty acid such as steric acid. Additional stabilizers may be provided. Furthermore, additives may be provided such as one or more healing promotion agents. In turn, a composition comprising collagen microbubbles may be facilitated that may have usefulness in a number of applications including, for example, wound care.
PROBLEM TO BE SOLVED: To provide a gel-like pressure-sensitive adhesive for a pasting agent with appropriate pressure-sensitive adhesive force on the surface of a skin and easily peelable properties. SOLUTION: This pasting agent consists of a pressure-sensitive adhesive agent wherein a polymer A contg. an acidic group or its salt, a polymer B contg. a basic group or its salt and a liq. ingredient C being compatible with the polymer A and the polymer B are incorporated and the polymers A and B and the liq. ingredient C are mixed at a ratio where the liq. ingredient C does not ooze out and consists of the adhesive and a substrate and has a pressure-sensitive adhesive force needed for preventing it from being released from the adhered surface of a skin.
The invention comprises compounds of the formula <FORM:0782427/IV (a)/1> where R is an alkoxy, aminosulphonyl or alkyl sulphonyl radical. The products are made by reaction of an acid halide of the formula <FORM:0782427/IV (a)/2> wherein X is a halogen atom, with ethyl mercaptan or a functional derivative thereof such as ethyl thiomagnesium bromide, preferably in the presence of an inert solvent or diluent and an acid binding agent such as caustic soda.  The products are used in pharmaceutical compositions.  Examples describe the preparation of the s-ethyl esters of p-ethylsulphonyl-thiolbenzoic, p-aminosulphonyl-thiolbenzoic and p-methoxy-thiolbenzoic acids.ALSO:Pharmaceutical compositions suitable for the treatment of tuberculosis comprise esters of the formula <FORM:0782427/VI/1> wherein R is an alkyl, aminosulphonyl or alkylsulphonyl radical, mixed with a pharmaceutical excipient.  The compounds may be used for example in pills, tablets, capsules or other pharmaceutical forms.  Examples describe compositions comprising ethyl p - ethylsulphonylthiolbenzoate and ethyl p-methoxythiolbenzoate mixed with arachis oil are suitable for intramuscular administration.
Sleep systems having embedded sensors are described. In one aspect, a sleep system includes a mattress and one or more force sensors embedded within the mattress. The force sensors are positioned within the mattress to sense movement of an occupant of the mattress. The sleep system also includes one or more processors coupled with the one or more force sensors. At least one of the processors is configured to determine sleep state information for the occupant based on data obtained from one or more of the force sensors. 1
BACKGROUD: Diabetic neuropathy (DN) is one of the most common complications of diabetes, affecting about half of individuals with the disease. Among the various symptoms of DN, the development of chronic pain stands out and manifests as exacerbated responses to sensorial stimuli. The conventional clinical treatments used for general neuropathy and associated painful symptoms, still brings uncomplete and unsatisfactory pain relief. Patients with neuropathic pain syndromes are heterogeneous. They present with a variety of sensory symptoms and pain qualities which difficult the correct diagnosis of sensory comorbidities and consequently, the appropriate chronic pain management.
AIMS: Herein, we aimed to demonstrate the existence of different sensory profiles on diabetic patients by investigating epidemiological and clinical data on the symptomatology of a group of patients with DN.
METHODS: This is a longitudinal and observational study, with a sample of 57 volunteers diagnosed with diabetes from outpatient day clinic of Hospital Universitário of the University of São Paulo-Brazil. After being invited and signed the Informed Consent Form (ICF), patients were submitted to clinical evaluation and filled out pain and quality of life questionnaires. They also performed quantitative sensory test (QST) and underwent skin biopsy for correlation with cutaneous neuropathology.
RESULTS: Data demonstrate that 70% of the studied sample presented some type of pain, manifesting in a neuropathic or nociceptive way, what has a negative impact on the life of patients with DM. We also demonstrated a positive association between pain and anxiety and depression, in addition to pain catastrophic thoughts. Three distinct profiles were identified in the sample, separated according to the symptoms of pain: (i) subjects without pain; (ii) with mild or moderate pain; (iii) subjects with severe pain. We also identified through skin biopsy that diabetic patients presented advanced sensory impairment, as a consequence of the degeneration of the myelinated and unmyelinated peripheral fibers. This study characterized the painful symptoms and exteroceptive sensation profile in these diabetic patients, associated to a considerable level of sensory degeneration, indicating, and reinforcing the importance of the long-term clinical monitoring of individuals diagnosed with DM, regarding their symptom profiles and exteroceptive sensitivity.
FIELD: organic chemistry, medicine, oncology, pharmacy. SUBSTANCE: invention relates to novel derivatives of substituted purinyl showing immunomodulating, in part, immunostimulating activity both in vivo and in vitro without toxicity, a pharmaceutical composition and a method of inhibition of the tumor growth. Derivatives of substituted purinyl or its pharmaceutically acceptable derivatives correspond to the formula (I)   where R 1  means substituted amino-group presented by the formula NR 5 R 6  where R 5  and R 6  are taken independently among the group consisting of hydrogen atom, C 1-4 -alkyl, cyclopropyl, 1-methyl-2-acetoxyethyl and unsubstituted amino-group; or R 5  R 6  taken in common with nitrogen atom to which they are bound form azethidine or methylaziridine under condition that R 5  and R 6  both do not mean hydrogen atom and that R 5  and R 6  both do not mean amino-group; R 2  and R 3  are taken independently among the group consisting of hydrogen atom, C 1-4 -alkyl, amino-group, mercapto- group, thiol substituted with C 1-4 -alkyl and halogen atom; R 4  means the formula -(CH 2 )-L-O-CO-X 12 , where L is taken among the group consisting of (CH 2 ) n -,-(CH 2 ) m -Q-(CH 2 ) m - and -(CH 2 ) m -C≡C-(CH 2 ) m - where Q means O, S, NH or CH 2  where X 12  means lower aminoalkyl group, amino acid taken among isoleucine, leucine, proline, arginine, glycine, alanine, glutamic acid, valine, ornithine or citrulline bound by its α-amino-group or peptide comprising 2-5 indicated amino acids; n is a whole number from 1 to 6; m is a whole number from 1 to 3 under condition that if R 1  means NH 2  and R 4  means pentyloxycarbonyl-L-arginine then R 2  does not mean hydrogen atom. Invention relates to also a pharmaceutical composition that comprises effective amount of compounds of the formula (I) and a pharmaceutically acceptable carrier. Invention relates to also a method of the growth inhibition by administration to mammal a compound of the formula (I). EFFECT: new compounds indicated above, valuable antitumor property. 14 cl, 10 tbl, 7 dwg
Use appropriate aseptic technique. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. RITUXAN should be a clear, colorless liquid. Do not use vial if particulates or discoloration is present.

Administration

Use a sterile needle and syringe to prepare RITUXAN. Withdraw the necessary amount of RITUXAN and dilute to a final concentration of 1 mg/mL to 4 mg/mL in an infusion bag containing either 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP. Gently invert the bag to mix the solution. Do not mix or dilute with other drugs. Discard any unused portion left in the vial.

Storage

Diluted RITUXAN solutions for infusion may be stored refrigerated at 2°C to 8°C (36°F to 46°F) for 24 hours. Diluted RITUXAN solutions for infusion have been shown to be stable for an additional 24 hours at room temperature. However, since RITUXAN solutions do not contain a preservative, diluted solutions should be stored refrigerated (2°C to 8°C). No incompatibilities between RITUXAN and polyvinylchloride or polyethylene bags have been observed.
Participants in the "single-dose protocol" group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14.
BACKGROUND: Pancreas transplantation is the most effective treatment to improve quality of life and overcome complications in patients with end-stage renal disease and diabetes mellitus. One of the main approaches for concurrent renal disease and diabetes mellitus which has been underutilized during the past decade is a pancreas transplant after kidney transplantation. Our study aimed to quantify outcomes following pancreas after kidney transplants (PAKs) in the United States from 2001 to 2020 with an emphasis on graft and patient survival.
METHODS AND MATERIALS: A retrospective registry analysis was performed by accessing the OPTN/UNOS database for PAKs that were performed in the United States from January 2001 to April 2020. The study population was divided into two subgroups: patients receiving a pancreas transplant between 2001 and 2010 and those receiving a pancreas transplant between 2011 and 2020.
RESULTS: The study examined a total number of 3706 PAK recipients; patients who received a PAK from January 2001 through December 2010 (n = 2892) and those who received a PAK from January 2011 to April 2020 (n = 814). The selection process of transplant recipients did not drastically change throughout the 2001-2010 and 2011-2020 periods. Length of stay at the hospital after the transplantation improved significantly in the 2011-2020 group relative to the 2001-2010 group (8.48 vs. 10.08 days, mean, p < 0.01). Additionally, more transplantation with 4-6 human leukocyte antigen mismatch occurred in the 2011-2020 group than in the 2001-2010 group (80.6% vs. 71.4%, p < 0.01). The pancreas preservation time of 13.35 h in the 2001-2010 group decreased significantly to 11.17 h in the 2011-2020 group (p < 0.001). The mean donor's amylase and lipase also decreased significantly in the 2011-2020 cohort. Significant graft survival improvement was observed in the 2011-2020 group compared to the 2001-2010 group after a long-term follow-up (p < 0.001). The mean Calculated Pancreas Donor Risk Index was 1.08 for the 2001-2010 group and 0.99 for the 2011-2020 group with a significant difference (p < 0.001).
CONCLUSION: The beneficial results and improved outcomes observed in PAK patients demonstrate the effectiveness of the operation for individuals in need of a pancreas transplant. PAKs can prove to be a meaningful solution to overcome long waiting times, decrease the donor-recipient imbalance, expand the donor pool, and overcome the current underutilization in order to improve the short- and long-term quality of life in the groups of interest.
The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.
Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes mellitus has been reported in patients taking somatropin. Patients with undiagnosed pre-diabetes and diabetes mellitus may experience worsened glycemic control and become symptomatic. Monitor glucose levels periodically in all patients receiving SOGROYA, especially in those with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or pre-diabetes should be monitored closely. The doses of antidiabetic agents may require adjustment when SOGROYA is initiated.
OBJECTIVE: Brain networks mediating vestibular perception of self-motion overlap with those mediating balance. A systematic mapping of vestibular perceptual pathways in the thalamus may reveal new brain modulation targets for improving balance in neurological conditions.
METHODS: Here, we systematically report how magnetic resonance-guided focused ultrasound surgery of the nucleus ventralis intermedius of the thalamus commonly evokes transient patient-reported illusions of self-motion. In 46 consecutive patients, we linked the descriptions of self-motion to sonication power and 3-dimensional (3D) coordinates of sonication targets. Target coordinates were normalized using a standard atlas, and a 3D model of the nucleus ventralis intermedius and adjacent structures was created to link sonication target to the illusion.
RESULTS: A total of 63% of patients reported illusions of self-motion, which were more likely with increased sonication power and with targets located more inferiorly along the rostrocaudal axis. Higher power and more inferiorly targeted sonications increased the likelihood of experiencing illusions of self-motion by 4 and 2 times, respectively (odds ratios = 4.03 for power, 2.098 for location).
INTERPRETATION: The phenomenon of magnetic vestibular stimulation is the most plausible explanation for these illusions of self-motion. Temporary unilateral modulation of vestibular pathways (via magnetic resonance-guided focused ultrasound) unveils the central adaptation to the magnetic field-induced peripheral vestibular bias, leading to an explicable illusion of motion. Consequently, systematic mapping of vestibular perceptual pathways via magnetic resonance-guided focused ultrasound may reveal new intracerebral targets for improving balance in neurological conditions. ANN NEUROL 2024;96:121-132.
Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
The invention discloses uric acid reducing tea and a preparation method thereof. The uric acid reducing tea is prepared from the following raw materials in parts by weight: 20-23 parts of gynostemma pentaphylla, 30-33 parts of radix puerariae, 12-15 parts of selenium-enriched tea, 12-15 parts of plantain seeds, 0.7-1 part of hawthorn fruits, 0.25-0.55 part of brown sugar and 0.25-0.55 part of honey. The preparation method comprises the following steps: 1, weighing the raw materials; 2, drying the raw materials; 3, grinding and uniformly mixing the raw materials; 4, preparing formulated fluid; 5, stir-frying the obtained product to obtain the uric acid reducing tea; and 6, packing the obtained product. The raw materials in the formula of the uric acid reducing tea provided in the invention supplement each other and are matched scientifically. With the adoption of the uric acid reducing tea, urate deposit can be dissolved and expelled, and uric acid level in a human body can be effectively reduced. The prepared uric acid reducing tea is safe without side effects, and has the advantages of suitable taste, low cost and good health-care effect. The preparation method of the uric acid reducing tea provided in the invention is simple in process, and is convenient to implement.
NBO will be conducted with inhalation of 100% oxygen. NBO will be used in conjunction with best medical practice.
INTRODUCTION: Despite the data demonstrating an increased utilization of hepatitis C virus (HCV)-viremic kidneys, the acceptance and incorporation of HCV-viremic kidneys are not universal. We aimed to identify regional differences and their temporal changes in the utilization of HCV-viremic kidneys.
METHODS: Using the Organ Procurement and Transplantation Network database, HCV-viremic kidneys utilized in kidney transplants from March 15, 2019, to March 14, 2023, were included. The utilization of HCV-viremic kidneys across the United States and center-level clustering of HCV-viremic donor kidney transplants into HCV NAT-negative recipients (HCV D+/R- transplants) using Gini coefficients were examined.
RESULTS: Significant regional variations were observed, with regions 3, 10, and 11 accounting for 51% of all HCV-viremic kidney utilization. Region 9 benefited the most from HCV-viremic kidney transplants with a high influx of kidney imports from other regions (284.9% gain). Region 8 and region 6 encountered the most substantial losses, with net losses of -44.2% and -41.1%, respectively. HCV D+/R- transplants were concentrated in specific high-volume centers, but trends indicated a gradual increase in a more equitable distribution across centers over time.
CONCLUSIONS: Significant variations can be observed in the utilization of HCV-viremic kidneys throughout the United States. These variations highlight opportunities for kidney transplant centers in specific regions to adopt policies for HCV-viremic kidney transplants, thereby expanding their donor pool. Encouragingly, an increasing number of kidney transplant centers are adopting HCV D+/R- kidney transplants, indicating positive progress. These trends suggest a more balanced access to HCV-viremic kidneys ahead.